Vertex's new spending absorbed most of its third-quarter revenue growth

Vertex Pharmaceuticals grew revenue 12% in the September 2026 quarter, and almost none of it reached the earnings line. Non-GAAP operating income, which leaves out stock compensation and acquisition costs, rose 2%, and non-GAAP earnings per share slipped below the level of a year earlier. The squeeze is deliberate. The company is paying now to turn a business that still earns most of its money from cystic fibrosis drugs into one with five commercial franchises, and it has just added a fourth and is preparing a fifth.

The arithmetic is simple. Combined non-GAAP spending on research, acquired research and selling and administration rose by an amount equal to 68% of the revenue gain, calculated from the reported figures. Roughly two dollars of every three in new sales went straight back out. Most of the extra selling cost is commercial build-out: a sales force for povetacicept, a kidney drug awaiting a US decision this month, support for the painkiller JOURNAVX, and PALSONIFY, a hormone-disorder drug that came with the Crinetics acquisition.

On the reported GAAP basis the fall looks far steeper, but for a different reason. Operating margin dropped to 20.7% from 38.6% a year earlier, because the quarter carried $502 million of acquisition-related costs, mostly cash payments for unvested Crinetics employee share awards plus deal fees. That charge belongs to closing the deal. The rise in running costs does not, and it continues.

Vertex raised its full-year guidance for combined non-GAAP spending to approximately $6.0 billion, from a range of $5.65 billion to $5.75 billion. Set against what it spent in the first nine months, the new guide implies roughly $1.75 billion in the fourth quarter, above last quarter's level. Charles Wagner, the chief financial officer, said "The stand-alone Vertex business remains at the high end of our prior range", and put the Crinetics share of the increase at about $250 million. Revenue guidance went up by only the amount PALSONIFY is expected to contribute. For this year, the acquisition adds far more to costs than to sales.

JOURNAVX shows why the spending has not yet paid back. It is a non-opioid pill for acute pain, and it is selling briskly: more than 750,000 prescriptions were filled last quarter, up more than 40% on the quarter before. Revenue grew 18%. Revenue per prescription fell from the quarter before, but that quarter was flattered: the company said in August that wholesalers had rebuilt stock after drawing it down in the first quarter. Three things sit between list price and net sales: payer discounts, wholesaler discounts and a patient-support program that covers people whose insurers do not yet pay for the drug. On top of those, Medicare Part D coverage that took effect on 1 July moved previously uncontracted prescriptions onto rebated prices, a one-time reset to net revenue.

The date when JOURNAVX revenue should start tracking prescriptions has slipped. In February management expected the discount to settle around the turn of this year; in May it said the discount would normalize by the end of the year; in August that became the first half of next year. Now the support program stays on until the middle of next year, after which the company expects the discount to settle at 50% to 60%, typical of a branded oral drug. Until then, more volume buys less revenue than the prescription count suggests.

The Crinetics deal also changed the balance sheet. Vertex had no debt at the end of last year and now carries $4.5 billion of term loans taken on to help pay for the acquisition. Interest on that borrowing sits below the operating line, so it adds to the pressure on net income rather than showing up in the spending guide.

That leaves the quarter hard to judge on its own numbers. The kidney sales force is already hired ahead of the povetacicept decision due on 30 November. An approval would put a new product behind costs Vertex is already carrying; a delay would leave those costs in place with less to sell.